الفهرس | Only 14 pages are availabe for public view |
Abstract This study was carried out in the period between September 2002 and December 2003 in EL-Minia university hospital including twenty five normotensive subjects, twenty-five hypertensive patients and twenty five hypertensive patients with renal failure on HD. To determine whether Sicam-1 contributes to the complication of these patients or not. Hypertensive patients and those on dialysis were selected on the basis of the following criteria; blood pressure 140/90 mm Hg or greater, the duration of it is not less than six months. At time of blood sampling none of the patients received any hypertensive treatment. The serum level of sICAM-1 was measured. Results were tabulated and statistically analyzed using SPSS analytic method, t-test and correlation coefficients” test. In the present study, there was highly significant difference increase between age for hypertensive group with hypertensive group on dialysis but no significant difference between hypertensive group on dialysis with normotensive subjects. As regards blood pressure, there was a highly significant difference increase between these group in both systolic and diastolic blood pressure. In the current study, there was a significant increase in Sicam-1 levels in group III than group II and I, in groupII than groupI. Aim of the work To evaluate the relationship between ICAM-1 and hypertension. Study the role of ICAM-1 in dialysis patients caused by hypertensive nephropathy. Conclusion The impairment of vascular endothelial function was obvious in hypertensive patients and in patients on HD. The changes of ICAM-1 could be accepted as biochemical criteria of vascular endothelial injury. s ICAM-1 increased in HD patients on top of hypertension and uncomplicated hypertension compared to normotensive subjects. Recommendations It is recommended that screening of s ICAM-1 in hypertensive patients and in hypertensive patients complicated with renal failure is to be taken more seriously into consideration as a marker for these disease activity and one of the strategies for prevention and treatment of the future. |